Related references
Note: Only part of the references are listed.Intratumoral Immunization: A New Paradigm for Cancer Therapy
Aurelien Marabelle et al.
CLINICAL CANCER RESEARCH (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
High efficiency cell-specific targeting of cytokine activity
Genevieve Garcin et al.
NATURE COMMUNICATIONS (2014)
The Dose-Dependent Tumor Targeting of Antibody-IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo
Teresa Hemmerle et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The function of Fcγ receptors in dendritic cells and macrophages
Martin Guilliams et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties
Edmund A. Rossi et al.
BIOCONJUGATE CHEMISTRY (2013)
Peripherally Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid Organs and Tumors in Mice
Iraklis C. Kourtis et al.
PLOS ONE (2013)
A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity
Stephen D. Gillies
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response
Katarzyna Franciszkiewicz et al.
CANCER RESEARCH (2012)
Immunocytokines: a novel class of potent armed antibodies
Nadine Pasche et al.
DRUG DISCOVERY TODAY (2012)
Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention
Richard K. Yang et al.
JOURNAL OF IMMUNOLOGY (2012)
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
Daniel J. Freeman et al.
MOLECULAR CANCER (2012)
Mouse Phenome Database (MPD)
Terry P. Maddatu et al.
NUCLEIC ACIDS RESEARCH (2012)
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
Paul M. Sondel et al.
ANTIBODIES (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
Stephen D. Gillies et al.
CLINICAL CANCER RESEARCH (2011)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Christoph Schliemann et al.
BLOOD (2009)
Intratumoral immunocytokine treatment results in enhanced antitumor effects
Erik E. Johnson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
Lucie Baudino et al.
JOURNAL OF IMMUNOLOGY (2008)
Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy
C Ebbinghaus et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
SD Gillies et al.
BLOOD (2005)
Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy
ZC Neal et al.
CLINICAL CANCER RESEARCH (2004)
Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor α-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect
BM Rao et al.
MOLECULAR PHARMACOLOGY (2004)
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
C Halin et al.
NATURE BIOTECHNOLOGY (2002)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
Share Paper
